Jefferies Financial Group and Regeneron Pharmaceuticals

Selected healthcare news for the capital firm - Jefferies Financial Group, and the company - Regeneron Pharmaceuticals. We have 51 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
6/20/2020 Recent Investment Analysts’ Ratings Updates for Regeneron Pharmaceuticals (REGN) American Banking News A number of research firms have changed their ratings and price targets for Regeneron Pharmaceuticals (NASDAQ: REGN): 6/12/2020 – Regeneron Pharmaceuticals had its price target raised by analysts at Jefferies Financial Group Inc from $657.00 to $691.00. They now have a “buy” rating on the stock. 6/10/2020 – Regeneron Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating. 6/2/2020 – Regeneron Pharmaceuticals had its price target raised ...
6/15/2020 Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $691.00 - Ticker Report Ticker Report Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective lifted by Jefferies Financial Group from $657.00 to $691.00 in a report released on Friday morning, The Fly reports. They currently have a buy rating on the biopharmaceutical company’s stock. A number of other equities research analysts also recently commented on the company. ValuEngine upgraded Regeneron Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, March ...
6/14/2020 Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $691.00 at Jefferies Financial Group Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $691.00 at Jefferies Financial Group Posted by Rex Bailey on Jun 13th, 2020 Tweet Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target hoisted by Jefferies Financial Group from $657.00 to $691.00 in a report released on Friday, The Fly reports. Jefferies Financial Group currently has a buy rating on the biopharmaceutical company’s stock. REGN has been the subject of several other reports ...
6/14/2020 Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $691.00 at Jefferies Financial Group Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $691.00 at Jefferies Financial Group Posted by Elaine Iseri on Jun 13th, 2020 Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by Jefferies Financial Group from $657.00 to $691.00 in a research note published on Friday, The Fly reports. Jefferies Financial Group currently has a buy rating on the biopharmaceutical company’s stock. A number of other research firms have also recently ...
6/14/2020 Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $691.00 at Jefferies Financial Group Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $691.00 at Jefferies Financial Group Posted by Jonathan Perkins on Jun 13th, 2020 Tweet Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by Jefferies Financial Group from $657.00 to $691.00 in a research note published on Friday, The Fly reports. Jefferies Financial Group currently has a buy rating on the biopharmaceutical company’s stock. A number of other research firms have also ...
6/14/2020 Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $691.00 | Daily Political Daily Political Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target hoisted by equities researchers at Jefferies Financial Group from $657.00 to $691.00 in a research report issued to clients and investors on Friday, The Fly reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price points to a potential upside of 17.44% from the stock’s previous close.Other analysts have also issued research reports about ...
6/14/2020 Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to “Hold” at BidaskClub - TheOlympiaReport ... Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a hold rating in a report released on Wednesday, BidAskClub reports. A number of other equities research analysts have also recently weighed in on the company. Evercore ISI raised Regeneron Pharmaceuticals from an in-line rating to an outperform rating and set a $500.00 price objective for the company in a research note on Monday, February 24th. Jefferies Financial Group reaffirmed ...
6/14/2020 Short Interest in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Increases By 11.8% Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was the recipient of a significant growth in short interest during the month of May. As of May 29th, there was short interest totalling 1,990,000 shares, a growth of 11.8 ... to a “hold” rating in a research report on Wednesday. Jefferies Financial Group boosted their price target on Regeneron Pharmaceuticals from $657.00 to $691.00 and gave the company a “buy” rating in a report on ...
6/14/2020 Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to “Hold” at BidaskClub Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to “Hold” at BidaskClub Posted by Steve Fairfield on Jun 14th, 2020 BidaskClub downgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a hold rating in a ... the company in a research note on Monday, February 24th. Jefferies Financial Group reaffirmed a buy rating and issued a $657.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, June ...
6/2/2020 Cantor Fitzgerald Raises Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $624.00 American Banking News Posted by ABMN Staff on Jun 2nd, 2020 // No Comments Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective hoisted by equities researchers at Cantor Fitzgerald from $400.00 to $624.00 in a research note issued on ... other research analysts also recently issued reports on the company. Jefferies Financial Group raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price objective for the company from $355.00 to ...
6/1/2020 Barclays Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $615.00 - TheOlympiaReport Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective increased by Barclays from $530.00 to $615.00 in a research report report published on Thursday, The Fly reports. A number of other equities research analysts also recently ... to $524.00 in a research note on Wednesday, May 6th. Jefferies Financial Group raised shares of Regeneron Pharmaceuticals from a hold rating to a buy rating and lifted their price target for the stock from ...
6/1/2020 Barclays Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $615.00 The Markets Daily Barclays Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $615.00 Posted by Danessa Lincoln on Jun 1st, 2020 // Comments off Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective increased by Barclays from $530.00 to $615.00 ... to $524.00 in a research note on Wednesday, May 6th. Jefferies Financial Group raised shares of Regeneron Pharmaceuticals from a hold rating to a buy rating and lifted their price target for the stock from ...
4/30/2020 Q1 2020 EPS Estimates for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Reduced by Analyst | Daily Political Daily Political Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Stock analysts at Jefferies Financial Group lowered their Q1 2020 EPS estimates for shares of Regeneron Pharmaceuticals in a report issued on Monday, April 27th. Jefferies Financial Group analyst B. Amin now forecasts that the biopharmaceutical company will post earnings per share of $4.89 for the quarter, down from their prior estimate of $5.91. Jefferies Financial Group currently has a “Buy” rating and a $492.00 ...
4/30/2020 Q1 2020 EPS Estimates for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Reduced by Analyst American Banking News Posted by ABMN Staff on Apr 30th, 2020 // No Comments Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Stock analysts at Jefferies Financial Group lowered their Q1 2020 EPS estimates for shares of Regeneron Pharmaceuticals in a report issued on Monday, April 27th. Jefferies Financial Group analyst B. Amin now forecasts that the biopharmaceutical company will post earnings per share of $4.89 for the quarter, down from their prior estimate of $5.91. Jefferies ...
4/29/2020 FY2021 EPS Estimates for Regeneron Pharmaceuticals Inc Lifted by Jefferies Financial Group (NASDAQ:REGN) American Banking News Posted by ABMN Staff on Apr 29th, 2020 // No Comments Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Investment analysts at Jefferies Financial Group lifted their FY2021 earnings per share estimates for shares of Regeneron Pharmaceuticals in a research report issued on Monday, April 27th. Jefferies Financial Group analyst B. Amin now forecasts that the biopharmaceutical company will post earnings per share of $29.95 for the year, up from their previous forecast of ...
4/18/2020 Regeneron Pharmaceuticals (NASDAQ:REGN) Given Daily Coverage Optimism Score of 1.83 American Banking News Regneron’s Potential Coronavirus Drug Makes the Stock a Buy, Analyst Says (finance.yahoo.com) Several equities analysts have weighed in on REGN shares. Argus raised their price target on Regeneron Pharmaceuticals from $430.00 to $540.00 and gave the company a “buy” rating in a report on Thursday, March 12th. Jefferies Financial Group upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price objective for the company from ...
4/18/2020 Regeneron Pharmaceuticals (NASDAQ:REGN) Trading Up 5.5% Following Analyst Upgrade Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) were up 5.5% during trading on Thursday after BMO Capital Markets raised their price target on the stock from $379.00 to $466.00. BMO Capital Markets currently has a ... outperform” rating in a research note on Wednesday, March 11th. Jefferies Financial Group upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the company from ...
8/14/2019 Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by Cowen Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by Cowen Posted by Elija Maina on Aug 14th, 2019 Regeneron Pharmaceuticals (NASDAQ:REGN) ‘s stock had its “hold” rating reiterated by stock analysts at Cowen in a note ... of Regeneron Pharmaceuticals in a report on Wednesday, May 8th. Jefferies Financial Group decreased their target price on Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating on the stock in a research ...
8/9/2019 BMO Capital Markets Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $344.00 January 2014 BMO Capital Markets Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $344.00 August 8th, 2019 - Comments Off on BMO Capital Markets Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $344.00 - Filed Under - by ... hold rating in a research report on Tuesday, June 18th. Jefferies Financial Group cut their price objective on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a hold rating on the stock in ...
8/9/2019 Robert W. Baird Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Outperform Robert W. Baird Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Outperform Posted by Trent Williams on Aug 9th, 2019 Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by stock analysts at Robert W. Baird from a “neutral” rating ... buy” rating in a research note on Tuesday, June 11th. Jefferies Financial Group reduced their target price on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating on the stock in ...
8/9/2019 BMO Capital Markets Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $344.00 BMO Capital Markets Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $344.00 Posted by David Glaser on Aug 9th, 2019 // Comments off Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lowered by analysts at BMO ... hold” rating in a research report on Tuesday, June 18th. Jefferies Financial Group decreased their target price on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating for the company in ...
8/7/2019 Regeneron Pharmaceuticals (NASDAQ:REGN) Given Neutral Rating at Credit Suisse Group Regeneron Pharmaceuticals (NASDAQ:REGN) Given Neutral Rating at Credit Suisse Group Posted by Donald Scott Aug 7th, 2019 Regeneron Pharmaceuticals (NASDAQ:REGN) ‘s stock had its “neutral” rating restated by Credit Suisse Group in a ... of Regeneron Pharmaceuticals in a report on Monday, July 29th. Jefferies Financial Group reduced their target price on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating for the company in ...
7/23/2019 Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Sell at BidaskClub Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Sell at BidaskClub Posted by Martin Roberts on Jul 23rd, 2019 BidaskClub upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong sell rating to a sell rating in a research report sent to investors on Friday, BidAskClub reports. Several other analysts have also recently weighed in on REGN. Jefferies Financial Group set a $158.00 price objective on shares of HCA Healthcare and ...
7/23/2019 Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Sell at BidaskClub Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Sell at BidaskClub Posted by Mitch Edgeman on Jul 23rd, 2019 // Comments off BidaskClub upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong sell rating to a sell rating in a research report sent to investors on Friday, BidAskClub reports. Several other analysts have also recently weighed in on REGN. Jefferies Financial Group set a $158.00 price objective on shares of HCA ...
7/20/2019 Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to “Sell” at BidaskClub Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to “Sell” at BidaskClub Posted by Renata Jones on Jul 20th, 2019 // Comments off Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by stock analysts at BidaskClub from a “strong sell” rating ... Anglo American in a research note on Wednesday, May 8th. Jefferies Financial Group set a $158.00 target price on shares of HCA Healthcare and gave the company a “buy” rating in a research note on ...